
Elon Musk’s company Neuralink announced Thursday that it received approval from the Food and Drug Administration (FDA) to conduct its first-in-human clinical study.
"We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study," the company said in a tweet.
Musk helped co-found Neuralink, a neurotechnology company working to develop brain implants that could someday help people who are paralyzed walk again, as well as help with other neurological issues.
Since 2019, Musk has been predicting that Neuralink would get approval from the FDA for human trials.
But in early 2022, Neuralink’s application was rejected, and since then, the company’s been working through concerns expressed by the FDA over the safety of the implant.